Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs
MWN-AI** Summary
Lucid Diagnostics Inc. has announced the appointment of Danielle Scelfo as Senior Vice President of Market Access & Government Affairs, a move aimed at strengthening the company’s market infrastructure in anticipation of critical reimbursement milestones. This strategic decision comes as Lucid seeks to enhance patient access to its EsoGuard® Esophageal DNA Test, particularly with the prospect of Medicare coverage on the horizon.
Scelfo brings over 25 years of experience in health policy, market access, and reimbursement strategies within the diagnostics sector, having held senior positions at notable companies such as ClearNote Health, CareDx, and Hologic. Her extensive background in the industry, combined with her leadership roles in various health policy initiatives, positions her as a key player in Lucid’s growth strategy.
According to Dr. Lishan Aklog, Lucid's Chairman and CEO, Scelfo's leadership is timely, coinciding with promising developments from the MolDX CAC meeting that bolstered the company’s outlook for Medicare coverage. The anticipated expansion of commercial insurance coverage for EsoGuard is expected to benefit from her expertise, as she will be responsible for enhancing engagement with payers and facilitating broader insurance access.
In her words, Scelfo expressed enthusiasm about joining Lucid at a pivotal moment, emphasizing her commitment to leveraging clinical evidence for the technology's commercialization and ensuring patients gain widespread access to Esophageal cancer prevention tools.
Lucid Diagnostics, a subsidiary of PAVmed Inc., specializes in innovative cancer prevention diagnostics, particularly focusing on patients at risk for esophageal precancer due to gastroesophageal reflux disease (GERD). The EsoGuard test represents a significant advancement in non-invasive cancer detection, aiming to reduce cancer-related mortality through early intervention.
MWN-AI** Analysis
Lucid Diagnostics, a key player in the cancer prevention diagnostics sector, has recently propelled itself into a crucial phase with the appointment of Danielle Scelfo as Senior Vice President, Market Access & Government Affairs. This strategic move is designed to bolster Lucid’s infrastructure in market access, particularly as it aims for Medicare coverage for its flagship product, the EsoGuard Esophageal DNA Test.
Scelfo’s extensive experience in the diagnostics field equips her to navigate the complex interplay of market access and reimbursement. Her history of engaging with payors and securing coverage enhances Lucid’s prospects, especially now that the company is poised for significant milestones—a sentiment echoed by CEO Lishan Aklog, who emphasized the importance of Scelfo’s role in capitalizing on positive outcomes from the recent Medicare review.
From a market perspective, investors should be keenly aware of the positive implications arising from this leadership change. The EsoGuard test addresses a critical health concern—esophageal precancer linked with GERD—allowing Lucid to cater to a substantial at-risk population. As more insurers consider coverage, potentially stimulated by Medicare’s positive indications, Lucid’s patient base could expand significantly, enhancing revenue projections.
However, while the outlook appears promising, investors should remain cognizant of inherent risks. Market dynamics, competitive pressures, and the regulatory landscape can lead to volatility in performance. Furthermore, although Lucid's robust clinical evidence supports its technologies, definitive approval and acceptance from payors remain paramount challenges.
In conclusion, with Scelfo’s acknowledgment of the urgent need for broad patient access, Lucid Diagnostics is at a pivotal junction. Stakeholders should monitor upcoming reimbursement developments closely to assess the company’s trajectory and potential market impacts, gauging both opportunities and risks that lie ahead.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs
PR Newswire
Scelfo to strengthen and scale Lucid's market access infrastructure ahead of key upcoming reimbursement milestones—including Medicare coverage for EsoGuard—and to accelerate commercial coverage expansion
NEW YORK , Sept. 16, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the appointment of Danielle Scelfo as Senior Vice President, Market Access & Government Affairs, reporting to the Chief Executive Officer. Ms. Scelfo is widely recognized in the diagnostics industry as an accomplished health policy leader with more than 25 years of strategic and operational experience across market access, reimbursement, and government affairs. She will oversee Lucid's rapidly expanding market access and reimbursement activities, focused on payor engagement and securing broad insurance coverage and patient access to its EsoGuard ® Esophageal DNA Test .
"Lucid is at an important inflection point as we seek to expand patient access to our groundbreaking EsoGuard test and unlock its substantial commercial opportunity. The recent extremely positive MolDX CAC meeting strengthens our confidence that Medicare coverage is within sight, and that we will be able to accelerate our ongoing positive engagements with commercial insurers on EsoGuard coverage," said Lishan Aklog , M.D. , Lucid's Chairman and Chief Executive Officer. "We are very excited to have Danielle join the Lucid team at this critical juncture. She is a widely respected, strategically focused market access professional with a proven track record of building successful teams that have secured broad coverage for molecular diagnostic tests across the industry. Her efforts will be powered by a clinical evidence package that panelists at the CAC meeting confirmed strongly supports EsoGuard's performance and clinical utility in detecting esophageal precancer before it progresses to cancer."
Ms. Scelfo most recently served as Vice President, Market Access & Health Policy at ClearNote Health, a commercial-stage cancer detection company focused on blood-based molecular tests. She previously held various senior market access, reimbursement, and health policy roles in the diagnostics sector, including leadership positions at CareDx, Inc., Hologic, Inc., Adaptive Biotechnologies Corporation, and Genomic Health, Inc. (now part of Exact Sciences, Inc.). Her early career experience included roles at UnitedHealthcare, Johnson & Johnson, and Sanofi S.A., formerly Sanofi-Aventis. She has also held prominent leadership positions in the diagnostics industry, including as Chair of the Coalition for 21st Century Medicine Reimbursement and Policy Workgroup and the California Healthcare Institute Diagnostic Workgroup, and contributed to multiple diagnostic CPT working groups for the American Medical Association.
"I am incredibly excited to join the Lucid team at this pivotal moment as the Company advances toward Medicare coverage and broader commercial insurance coverage of EsoGuard," said Ms. Scelfo. "I look forward to working closely with Lucid leadership to leverage the strong clinical evidence supporting this groundbreaking technology to drive widespread payor coverage, build a best-in-class market access team, and advance policies that secure broad coverage and access for patients."
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard ® Esophageal DNA Test , performed on samples collected in a brief, noninvasive office procedure with its EsoCheck ® Esophageal Cell Collection Device , represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For more information about Lucid, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com .
Forward-Looking Statements
This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of Lucid's management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of Lucid's common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance Lucid's products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from Lucid's clinical and preclinical studies; whether and when Lucid's products are cleared by regulatory authorities; market acceptance of Lucid's products once cleared and commercialized; Lucid's ability to raise additional funding as needed; and other competitive developments. In addition, Lucid continues to monitor the COVID-19 pandemic and the pandemic's impact on Lucid's businesses. These factors are difficult or impossible to predict accurately and many of them are beyond Lucid's control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect Lucid's future operations, see Part I, Item 1A, "Risk Factors," in Lucid's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its most recent Annual Report. Lucid disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.
SOURCE Lucid Diagnostics
FAQ**
How will Danielle Scelfo’s appointment as Senior Vice President, Market Access & Government Affairs impact Lucid Diagnostics Inc. (LUCD) efforts to secure Medicare coverage for the EsoGuard Esophageal DNA Test?
What specific strategies does Scelfo plan to implement at Lucid Diagnostics Inc. (LUCD) to accelerate commercial coverage expansion for EsoGuard?
With Scelfo’s extensive experience in market access and reimbursement, how does Lucid Diagnostics Inc. (LUCD) envision her role evolving as they approach key reimbursement milestones?
What are the potential implications for Lucid Diagnostics Inc. (LUCD) if Medicare coverage for EsoGuard is achieved, following the recent positive outcomes from the MolDX CAC meeting?
**MWN-AI FAQ is based on asking OpenAI questions about Lucid Diagnostics Inc. (NASDAQ: LUCD).
NASDAQ: LUCD
LUCD Trading
-1.07% G/L:
$1.385 Last:
147,261 Volume:
$1.41 Open:
